"A multispecialty community and teaching hospital providing quality health care services to the residents of Greater New Britain, Connecticut."

During the past decade, George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 40 clinical trials were completed, i.e. on average, 444.4% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 13 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus" #1 sponsor was "Gynecologic Oncology Group" with 10 trials, followed by "Celgene" with 7 trials sponsored, "Radiation Therapy Oncology Group" with 6 trials sponsored, "Alliance for Clinical Trials in Oncology" with 4 trials sponsored and "Bristol-Myers Squibb" with 4 trials sponsored. Other sponsors include 18 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus" #1 collaborator was "National Cancer Institute (NCI)" with 23 trials as a collaborator, "NRG Oncology" with 6 trials as a collaborator, "Cancer and Leukemia Group B" with 2 trials as a collaborator, "Aptuit" with 1 trials as a collaborator and "Bristol-Myers Squibb" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus" are "Fallopian Tube Cancer" (5 trials), "Ovarian Cancer" (5 trials), "Lung Cancer" (4 trials), "Multiple Myeloma" (4 trials) and "Primary Peritoneal Cavity Cancer" (4 trials). Many other conditions were trialed in "George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus" in a lesser frequency.

Most popular intervention types in "George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus" are "Drug" (46 trials), "Biological" (12 trials), "Radiation" (9 trials), "Other" (4 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Lenalidomide" (5 trials), "Paclitaxel" (5 trials), "Placebo" (4 trials), "cetuximab" (4 trials) and "Dexamethasone" (3 trials). Other intervention names were less common.

The vast majority of trials in "George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus" are 40 trials for "All" genders, 12 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus". undefined are not yet recruiting, undefined are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 43 completed trials in George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus, 2 "Phase 1" clinical trials were conducted, 24 "Phase 2" clinical trials and 28 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".